Billionaire investor Ronald Burkle said the poison-pill plan that Barnes & Noble Inc. enacted to stop him from taking a larger share in the company has imposed draconian restrictions on his ability to wage a potential proxy fight against the Riggio family which controls the bookseller.
Testifying at a civil trial in Delaware Chancery Court, Mr. Burkle said the shareholder-rights plan's rules were so confusing and far reaching that he hasn't even been returning the calls of other Barnes & Noble shareholders for fear of tripping certain regulations. He said his investment firm, Yucaipa Cos., may wage a proxy battle to replace three Barnes & Noble board members, but the rules have made it nearly impossible to determine if the proxy would pass.
Barnes & Noble adopted the rights plan last November in an effort to halt Burkle's rapid accumulation of shares. Yucaipa holds about 18.7 percent of Barnes & Noble's outstanding shares, while the threshold for triggering the rights plan is 20 percent.
• Read the full New York Times story.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Barnes & Noble Stockholders Snub Burkle
- Burkle Loses Bid to Overturn B&N Poison Pill
- Proxy Advisor Supports Barnes & Noble in Burkle Contest
- Burkle's Yucaipa Sues Barnes & Noble Over 'Poison Pill'
- Billionaire’s New Interest in Bookseller a Thriller
- Burkle’s Way-Too-Personal Touch
- Barnes & Noble Accuses Burkle of 'Corporate Failures'
- Burkle Targets Barnes & Noble